ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals.

Employees

3,853

Sector

Pharmaceuticals

Calendar

2025-01-30 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-02	1,742.50 ¥	+0.55%	705,400
24-12-02	1,733.00 ¥	+0.06%	1,579,800
24-11-29	1,732.00 ¥	+0.38%	1,625,500
24-11-28	1,725.50 ¥	+0.67%	1,477,500
24-11-27	1,714.00 ¥	-1.04%	1,537,800

Delayed Quote Japan Exchange, December 02, 2024 at 01:30 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart ONO-PHARMACEUTICAL-CO-LTD

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,733.00JPY

Average target price

2,086.15JPY

Spread / Average Target

+20.38%

Consensus

Profit revisions

estimates-change-chart ONO-PHARMACEUTICAL-CO-LTD

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart ONO-PHARMACEUTICAL-CO-LTD

Company calendar

Delayed Japan Exchange Other stock markets 09:30:00 2024-12-02 pm EST			5-day change	1st Jan Change
1,742.50 ^JPY	+0.55%		+0.61%	-30.74%

Nov. 20	C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors	CI
Oct. 31	Top Midday Decliners	MT

Capitalization	814B 5.44B 5.18B 4.82B 4.3B 7.64B 460B 8.41B 59.41B 22.17B 189B 20.43B 19.99B	P/E ratio 2025 *	12.9x	P/E ratio 2026 *	11.1x
Enterprise value	865B 5.78B 5.51B 5.13B 4.57B 8.12B 489B 8.94B 63.13B 23.56B 201B 21.71B 21.24B	EV / Sales 2025 *	1.79x	EV / Sales 2026 *	1.61x
Free-Float	79.73%	Yield 2025 *	4.62%	Yield 2026 *	4.63%

C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors	Nov. 20	CI
Top Midday Decliners	Oct. 31	MT
LigaChem Biosciences Signs $700 Million License Deal for Anti-Cancer Drug	Oct. 11	MT
Jefferies Adjusts Ono Pharmaceutical's Price Target to 1,800 Yen From 2,300 Yen, Keeps at Hold	Sep. 23	MT
Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera?s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor	Aug. 15	CI
Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics	Aug. 01	RE
Jefferies Adjusts Ono Pharmaceutical's Price Target to 2,300 Yen From 2,400 Yen, Keeps at Hold	Jul. 30	MT
European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor	Jul. 18	CI
Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion	Jun. 11	DJ
Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion	Jun. 11	MT
Ono Pharmaceutical Co., Ltd. completed the acquisition of Deciphera Pharmaceuticals, Inc. from BlackRock, Inc., Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.	Jun. 10	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week	Apr. 29	MT

Jefferies Adjusts Ono Pharmaceutical's Price Target to 1,800 Yen From 2,300 Yen, Keeps at Hold	Sep. 23	MT
Jefferies Adjusts Ono Pharmaceutical's Price Target to 2,300 Yen From 2,400 Yen, Keeps at Hold	Jul. 30	MT
Jefferies Adjusts Ono Pharmaceutical’s Price Target to 2,400 Yen From 2,300 Yen, Keeps at Hold	Mar. 11	MT
Jefferies Adjusts Ono Pharmaceutical’s Price Target to 2,300 Yen From 2,500 Yen, Keeps at Underperform	23-05-30	MT
Jefferies Downgrades Ono Pharmaceuticals to Underperform From Hold, Adjusts Price Target to 2,500 Yen From 3,000 Yen	23-03-07	MT

Ono Pharmaceutical Co., Ltd. Stock

Equities

4528

JP3197600004

Pharmaceuticals

Valuation: Ono Pharmaceutical Co., Ltd.

Chart: Ono Pharmaceutical Co., Ltd.

Latest news: Ono Pharmaceutical Co., Ltd.

Last Transcript: Ono Pharmaceutical Co., Ltd.

Analysts' recommendations: Ono Pharmaceutical Co., Ltd.

Press Releases: Ono Pharmaceutical Co., Ltd.

News in other languages: Ono Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Ono Pharmaceutical Co., Ltd.

ETFs: Ono Pharmaceutical Co., Ltd.

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Ono Pharmaceutical : Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer	Nov. 18	PU
Ono Pharmaceutical : Revisions of Consolidated Financial Forecasts and Introduction of Core Basis in Financial Results	Oct. 30	PU
Ono Enters into License Agreement for LCB97, an Antibody-Drug Conjugate, and Research Collaboration and License Agreement to generate novel ADC Candidates by leveraging ConjuAll ADC platform with LigaChem Biosciences	Oct. 11	AQ
Ono Pharmaceutical - Opdivo Intravenous Infusion Approved in Taiwan in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	Oct. 11	AQ
Ono Pharmaceutical : Enters into License Agreement for LCB97, an Antibody-Drug Conjugate, and Research Collaboration and License Agreement to generate novel ADC candidates by leveraging ConjuAll™ ADC platform with LigaChem Biosciences	Oct. 10	PU

El Nikkei cae un 0,5% arrastrado por los valores electrónicos y farmacéuticos -- Market Talk	23-06-27
El Nikkei cae un 0,4%, arrastrado por las farmacéuticas y las siderúrgicas -- Market Talk	23-05-10
Nuevas compras en la cartera Inversor Asia	23-02-24
Nouveaux achats dans le portefeuille Investisseur Asie	23-02-24
Nieuwe reeks stijgingen voor onze 3 selecties	22-12-06

1 day	+0.06%
1 week	-0.83%
Current month	+0.06%
1 month	-11.49%
3 months	-19.62%
6 months	-23.82%
Current year	-31.12%

Director	Title	Age	Since
Gyo Sagara CEO	Chief Executive Officer	66	2024-03-31
Toichi Takino PSD	President	55	2024-03-31
Shinji Takai CTO	Chief Tech/Sci/R&D Officer	-	-

Manager	Title	Age	Since
Gyo Sagara CHM	Chairman	66	2024-03-31
Toichi Takino BRD	Director/Board Member	55	-
Masao Nomura BRD	Director/Board Member	75	2018-06-25

Name	Weight	AuM	1st Jan change	Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY	3.23%	16 M€	+11.87%
NEXT FUNDS SOLACTIVE JAPAN ESG CORE INDEX ETF - JPY	0.67%	247 M€	+17.55%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ONO PHARMACEUTICAL CO., LTD.	+0.06%	-0.83%	-36.00%	-30.22%	5.41B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+1.55%	+0.74%	+46.89%	+142.64%	50.52B
OTSUKA HOLDINGS CO., LTD.	+1.89%	-0.68%	+54.59%	+118.44%	31.09B
SANDOZ GROUP AG	-3.09%	-4.19%	+51.42%	-	19.97B
CIPLA LIMITED	-1.71%	+1.43%	+25.05%	+62.44%	14.65B
ZYDUS LIFESCIENCES LIMITED	+0.89%	+2.69%	+52.34%	+114.56%	11.49B
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	6.79B
STADA ARZNEIMITTEL	-.--%	-1.95%	-	-	5.73B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.52%	+9.11%	+4.56%	+23.82%	5.36B
GLENMARK PHARMACEUTICALS LIMITED	+1.24%	+4.69%	+95.25%	+208.62%	5.1B
Average	+0.03%	+0.54%	+36.76%	+91.47%	15.61B
Weighted average by Cap.	+0.41%	-0.32%	+44.41%	+114.46%

	2025 *	2026 *
Net sales	484B 3.24B 3.08B 2.87B 2.56B 4.55B 274B 5B 35.35B 13.19B 112B 12.16B 11.9B	516B 3.45B 3.28B 3.06B 2.73B 4.84B 292B 5.33B 37.64B 14.04B 120B 12.94B 12.67B
Net income	63.64B 425M 405M 377M 336M 597M 36B 657M 4.64B 1.73B 14.76B 1.6B 1.56B	73.26B 490M 467M 434M 387M 688M 41.44B 757M 5.35B 1.99B 16.99B 1.84B 1.8B
Net Debt	51.06B 341M 325M 303M 270M 479M 28.89B 527M 3.73B 1.39B 11.85B 1.28B 1.25B	16.64B 111M 106M 98.61M 87.95M 156M 9.41B 172M 1.21B 453M 3.86B 418M 409M